Adicet Bio

ACET

Market cap $1.22B

7.93 USD

+0.06

0.76%

At close Updated Dec 30, 4:00 PM EST

Pre-market

After hours

7.77

-0.16

2.02%

1 day

0.76%

5 days

1.28%

1 month

-18.75%

3 months

-38.81%

6 months

-18.75%

Year to date

-49.1%

1 year

-44.97%

5 years

-96.48%

10 years

-99.58%

About: Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Employees: 152

Healthcare Biotechnology